Biopharmaceutical research companies are conducting or have conducted nearly 3,500 clinical trials of new medicines in collaboration with the state’s clinical research centers, university medical schools and hospitals (1999 to present).

Of the nearly 3,500 clinical trials, 1,775 target or have targeted the nation’s six most debilitating chronic diseases—asthma, cancer, diabetes, heart disease, mental illnesses and stroke.

“Because of its strong research infrastructure, which includes the National Institutes of Health (NIH), Johns Hopkins University and the University of Maryland, Maryland is competitive with some much larger states in its number of clinical trials of new medicines. The nation’s biopharmaceutical research companies have conducted nearly 3,500 new drug tests in the state since 1999 in collaboration with these widely respected institutions and many others." --Douglas A. Doerfler, Vice Chairman, MdBio Division, Tech Council of Maryland